News
EQS-Adhoc: KION GROUP AG: Adjusted EBIT and free cash flow at Group level in Q1 2023 better than expected due to strong ITS segment; order volume in SCS segment below market expectations; outlook 2023 increased
EQS-Adhoc: KION GROUP AG: Adjusted EBIT and free cash flow at Group level in Q1 2023 better than expected due to strong ITS segment; order volume in SCS segment below market expectations; outlook 2023 increased
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
CTS EVENTIM founds EDGE, a paid media agency for the entertainment market
CTS EVENTIM founds EDGE, a paid media agency for the entertainment market
EQS-News: SAF-HOLLAND SE: Scope rating agency assigns investment grade rating BBB-
EQS-News: SAF-HOLLAND SE: Scope rating agency assigns investment grade rating BBB-
EQS-News: PNE Group with very strong growth in PPA consulting services
EQS-News: PNE Group with very strong growth in PPA consulting services
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-News: Hypoport SE: volume of mortgage finance increases slightly in the first quarter of 2023 compared with the extremely weak fourth quarter of 2022
EQS-News: Hypoport SE: volume of mortgage finance increases slightly in the first quarter of 2023 compared with the extremely weak fourth quarter of 2022
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-Adhoc: Deutsche Beteiligungs AG: Publication of a new forecast for the financial year 2022/2023
EQS-Adhoc: Deutsche Beteiligungs AG: Publication of a new forecast for the financial year 2022/2023
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
EQS-News: Vantage Towers AG: Management Board and Supervisory Board of Vantage Towers recommend the acceptance of the public delisting tender offer of Oak Holdings GmbH
EQS-News: Vantage Towers AG: Management Board and Supervisory Board of Vantage Towers recommend the acceptance of the public delisting tender offer of Oak Holdings GmbH
EQS-Adhoc: GRAMMER Aktiengesellschaft: Revenue and earnings development in the first quarter of 2023 significantly above previous year's level
EQS-Adhoc: GRAMMER Aktiengesellschaft: Revenue and earnings development in the first quarter of 2023 significantly above previous year's level
EQS-News: Mutares publishes annual report 2022 and records renewed growth: Mutares Holding's net income rises to record level of EUR 72.9 million in 2022 and is expected to continue to grow strongly in 2023
EQS-News: Mutares publishes annual report 2022 and records renewed growth: Mutares Holding's net income rises to record level of EUR 72.9 million in 2022 and is expected to continue to grow strongly in 2023
Holcim launches ECOCycle® to scale up circular construction
Holcim launches ECOCycle® to scale up circular construction
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed
EQS-Adhoc: MTU Aero Engines AG: Key figures of MTU Aero Engines AG in the first quarter 2023 exceed market expectations
EQS-Adhoc: MTU Aero Engines AG: Key figures of MTU Aero Engines AG in the first quarter 2023 exceed market expectations
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)